Knowledge graph · Drug
Anagrelide
small molecule
- Identifier
- CI-DRUG-00000699
- Entity page
- /drug/anagrelide ↗
- Edges
- 20
- Neighbours
- 4 cancers2 genes2 trials10 approvals
- Drawn
- 18 of 18 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Anagrelide approved for …APPROVED_FOR11 of 10 | ||||||||
| → approved for | Myeloproliferative Neoplasmhematologic_malignancy | supports | FDA ORIG | Myeloproliferative Neoplasm | 1 | Regulatory | openfda | graph → |
| → approved for | EMA · EU · 2018Anagrelide Viatris is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patient An at-risk essential thrombocythaemia patient is defined by one or more of the following features: >60 years of age or a platelet count >1,000 x 10⁹/l or a history of thrombo-haemorrhagic events. | |||||||